Histamine: A Comprehensive Reference
1. Identity, Chemical Nomenclature, and Natural Sources
Chemical Identity
Histamine (2-[4-imidazolyl]ethylamine) is a bioactive amine synthesized by decarboxylation of its precursor amino acid, histidine, in an enzymatic reaction first described by Windaus and Vogt in 1907, involving L-histidine decarboxylase (EC 4.1.1.22). The chemical formula for histamine is C5H9N3, classifying it as a biogenic amine synthesized from an amino acid precursor. Its architecture is composed of two primary functional groups: a five-membered heterocyclic ring called the imidazole ring and a two-carbon side chain known as the ethylamine group. The imidazole ring contains two nitrogen atoms, which gives the molecule its unique chemical reactivity. A defining characteristic of the imidazole ring is its ability to undergo tautomerism, a phenomenon where a single hydrogen atom can rapidly switch its position between the two nitrogen atoms in the ring, resulting in two slightly different, yet interchangeable, structural forms.
Early on, histamine was referred to by its chemical name, Ξ²-imidazolylethylamine (Dale and Laidlaw, 1910). Soon afterwards, the name "histamine" was adopted to denote its derivation from histidine, from the Greek word for tissue, "histos" (ΞΉΟΟΟΟ) (Dale and Richards, 1918).
Endogenous Sources and Cellular Distribution
Histamine is an organic nitrogenous compound found in mammals and many vegetables, fruits, and food products. In mammals, it is found within granules of basophils and mast cells (more than 90% of body stores) and within tuberomammillary neurons of the central nervous system. The enzyme HDC (L-histidine decarboxylase) is widely expressed in multiple cell types throughout the body, including gastric mucosal cells, neurons, gastric parietal cells, mast cells, and basophils. Among histamine-producing cells, mast cells and basophils are unique in their ability to synthesize, store, and release large quantities of histamine.
Dietary and Exogenous Sources
Histamine is also found in foods, mainly fish, fish products, and fermented foodstuffs. The major pathway for the formation of histamine in foods is the decarboxylation of its precursor amino acid, histidine, by the action of the bacterial enzyme L-histidine decarboxylase. Biogenic amines are natural components of animal and plant raw materials. Their increased content in foods results from the activity of endogenous enzymes or from the microbial decarboxylation of amino acids during controlled or spontaneous fermentation, processing, storage, and distribution.
Major dietary sources of histamine include:
- Scombroid fish (tuna, sardines, anchovies, mackerel, and salmon) β poisonings occur when these species, which contain high levels of muscle histidine, are temperature-abused, allowing bacteria to convert muscle histidine to histamine.
- Fermented sausages, cheese, fish sauces, and fermented vegetables are among the highest-ranked food categories for histamine exposure.
- Significant histamine levels are also detected in wine, kimchi, and soybeans due to naturally present or added yeast activity during preparation and fermentation.
- Canned sauerkraut has been reported to contain a high histamine concentration, with an average of 4.07 mg/100g in tested samples.
Common Forms and Preparations
Histamine itself is encountered in several contexts relevant to health and supplementation:
- Endogenous histamine β produced and stored in mast cells, basophils, and histaminergic neurons throughout the body.
- Dietary histamine β ingested via histamine-containing foods.
- Diamine oxidase (DAO) supplements β typically derived from porcine kidney extracts (the most common and biologically active, well-studied form) or from plant-based or microbial sources.
- Antihistamine pharmaceuticals β H1, H2, H3, and H4 receptor antagonists used therapeutically (not classified as dietary supplements, but directly related to histamine pharmacology).
2. Historical and Traditional Use
Pre-scientific Observations
Allergic diseases were described by medicine since ancient times, without exactly understanding the physio-pathologic mechanisms of immuno-mediated reactions and of their most important biochemical mediator, histamine. Key historical and scientific insights into the histamine molecule and its mechanism of action have been traced starting from Egyptian, Greek, and Chinese antiquity to more recent pharmacological and molecular discoveries. While the molecule itself was unknown to ancient practitioners, the clinical phenomena now understood to be histamine-mediated β urticaria, anaphylaxis-like reactions, itching, and flushing β were observed and treated empirically across multiple civilizations.
Scientific Discovery (20th Century)
The chemical synthesis of histamine (Windaus and Vogt, 1907) and its production from histidine by putrefactive bacteria (Ackermann, 1910) were reported in the first decade of the 20th century, before the recognition of its biological significance. Shortly afterwards, along with its isolation from the extract of the rye fungus ergot (Claviceps purpurea), Sir Henry H. Dale working with George Barger and Sir Patrick Laidlaw at the Wellcome laboratories in London pioneered the investigation of histamine physiology by conducting a series of biological assays in frogs, rodents, cats, and dogs.
The actions of histamine reported over 100 years ago were described as "somewhat complicated," exhibiting variations between different organs and species. These included smooth muscle contraction, vasodilatation, and depression of the CNS. Attention was also drawn to the ability of histamine to mimic the immediate symptoms of hypersensitivity reactions, which had been described as anaphylaxis (Portier and Richet, 1902) or allergy (von Pirquet and Schick, 1905) a few years earlier.
Discovered in 1910, histamine has been considered a local hormone (autocoid) because it is produced without involvement of the classic endocrine glands; however, in recent years, histamine has been recognized as a central neurotransmitter.
Research on histamine and allergic mechanisms started at the beginning of the 20th century with the first experimental observations on animals of anaphylactic reactions. Histamine was then identified as the major mediator of many allergic diseases and anaphylaxis, but also of several physiologic body functions.
Histamine was identified in 1910 by Dale and Laidlaw and has been recognized since the 1920s as a major mediator of allergic disorders such as asthma, rhinitis, anaphylaxis, and urticaria. Until 1966, when the H1-histamine receptor was identified, the precise mechanism of action of histamine remained unknown. Knowledge about the histaminergic system evolved with the subsequent discovery of the H2-receptor, involved in gastric acid secretion, and the H3-receptor, represented most prominently in the CNS.
First described more than 60 years ago, the deleterious effects of excessive histamine ingestion were initially referred to as scombroid fish poisoning or scombrotoxicosis, as they were associated with the consumption of fish in this family.
Histamine has since become one of the most well-researched substances in biomedical science, linked to multiple Nobel Prize awards.
3. Key Constituents and Biochemistry
Biosynthesis
Histamine is a biogenic amine synthesized from the amino acid L-histidine exclusively by the enzyme L-histidine decarboxylase (HDC), which requires pyridoxal-5β²-phosphate as an essential cofactor. L-histidine is carried to the histaminergic nerve terminals by the L-amino acid transporter.
Storage and Release
Histidine decarboxylase (HDC) synthesizes histamine from histidine. Histamine is stored in synaptic vesicles via vesicular monoamine transporter 2 (VMAT2). Upon stimulation, histamine is released to extraneuronal spaces. As part of an immune response to foreign pathogens, histamine is produced by basophils and by mast cells found in nearby connective tissues.
Catabolism and Inactivation
There are two different enzymes for the inactivation of histamine: diamine oxidase (DAO) (EC 1.4.3.22) and histamine N-methyltransferase (HNMT). The physiological actions of histamine are controlled not only by the receptors but also by the inactivating enzyme HNMT (EC 2.1.1.8). HNMT occurs ubiquitously in vertebrate species and is widely expressed in mammalian tissues, with particularly high expression levels in the kidney, liver, colon, prostate, ovary, and spinal cord cells. DAO operates predominantly in the extracellular space of the intestinal tract, while HNMT acts intracellularly throughout the body.
4. Mechanisms of Action: The Four Histamine Receptors
Histamine is a bioactive amine that acts as a signaling molecule and neurotransmitter. It exerts its diverse biological effects through the activation of four types of membrane-bound receptors from the aminergic G protein-coupled receptor (GPCR) family: H1, H2, H3, and H4 (named according to their order of discovery).
H1 Receptor
The H1 receptor is primarily located on smooth muscle cells, endothelial cells, and neurons. Activation of H1 receptors mediates various responses, including smooth muscle contraction (leading to bronchoconstriction, intestinal cramping), increased vascular permeability (resulting in edema), and stimulation of sensory nerve endings (causing itching and pain). The H1 receptor is widely distributed throughout the body, with well-documented expression in the CNS, smooth muscle, sensory nerves, heart, adrenal medulla, as well as immune, endothelial, and epithelial cells.
H2 Receptor
The H2 receptor is found mainly in the stomach lining (parietal cells) and regulates gastric acid secretion by stimulating the production of hydrochloric acid. H2 antagonists (H2 blockers) are used to reduce stomach acid production and treat conditions like gastroesophageal reflux disease (GERD) and peptic ulcers. H2 receptors are also present in the heart and vascular smooth muscle cells, where they contribute to cardiac rhythm regulation and vasodilation.
H3 Receptor
The H3 and H4 receptors are primarily coupled to Gi/o proteins, leading to the inhibition of adenylate cyclase and a consequent decrease in intracellular cAMP levels. The H3 receptor is predominantly expressed in the central and peripheral nervous systems, where it acts as a presynaptic autoreceptor regulating the synthesis and release of histamine and other neurotransmitters. H3 receptors are primarily located in the brain and are involved in modulating neurotransmitter release, including histamine itself, dopamine, serotonin, and acetylcholine. These receptors play a key role in regulating sleep, appetite, and cognitive functions. The autoregulatory function of H3 receptors on histamine release is crucial for maintaining neurotransmitter balance in the brain.
H4 Receptor
The H4 receptor is predominantly expressed on hematopoietic cells, particularly within immune cell populations β including mast cells, eosinophils, dendritic cells, and T lymphocytes β where it plays a key role in mediating chemotaxis, cytokine release, and inflammatory responses. Due to its prominent involvement in immune cell regulation, the H4 receptor is often referred to as the "immune system histamine receptor" and has been implicated in the pathogenesis of inflammatory and autoimmune diseases.
Downstream Signaling
Through its various receptor-mediated pathways, histamine plays a critical role in immunomodulation, regulating the activity, differentiation, and cytokine production of T cells, B cells, monocytes, and dendritic cells within lymphoid organs and peripheral tissues during allergic and inflammatory responses. Notably, interferon-Ξ³ production is enhanced by histamine stimulation of Th1 cells, which express high levels of H1 receptors and relatively low levels of H2 receptors.
5. Body Systems and Health Areas
Immune System and Allergic Response
Histamine is ubiquitously distributed throughout the body; however, it is stored in particularly high concentrations within the secretory granules of mast cells, especially in the lung parenchyma and airway mucosa, as well as in circulating basophils, where it is released upon immune activation. Histamine is a potent vasoactive molecule that exerts diverse effects on bronchial smooth muscle, vascular endothelium, and nociceptive sensory nerves, thereby contributing to bronchoconstriction, increased vascular permeability, and related effects. Histamine released during allergic and inflammatory responses increases vascular permeability and promotes vasodilation, leading to edema. H1 antihistamines act as antagonists at H1 receptors to mitigate these effects, relieving allergy symptoms.
Gastrointestinal System
In humans, histamine is involved in local immune response communication, as well as regulating physiological functions in the gut and acting as a neurotransmitter for the brain, spinal cord, and uterus. In the stomach, H2 receptor activation by histamine on parietal cells drives hydrochloric acid secretion β a well-established mechanism underpinning the therapeutic rationale for H2 blockers in peptic ulcer disease and GERD. Reduced DAO activity may result in excess histamine reaching systemic circulation and triggering a variety of non-specific intestinal and extra-intestinal symptoms, such as bloating, diarrhea, headache, dizziness, urticaria, or rhinorrhea, among others.
Central Nervous System: Sleep, Arousal, and Cognition
The tuberomammillary nucleus is the sole neuronal source of histamine in the brain, and like many of the arousal systems, histamine neurons diffusely innervate the cortex, thalamus, and other wake-promoting brain regions. New research demonstrates that activity in histamine neurons is essential for normal wakefulness, especially at specific circadian phases, and reducing activity in these neurons can produce sedation.
Strong and consistent evidence exists to suggest that histamine, acting via H1 and/or H3 receptors, has a pivotal role in the regulation of sleep-wakefulness. Administration of histamine or H1 receptor agonists induced wakefulness, whereas administration of H1 receptor antagonists promoted sleep. Histamine release in the hypothalamus and other target regions was highest during wakefulness. Histaminergic neurons displayed maximal activity during the state of vigilance and ceased their activity during NREM and REM sleep.
Functioning as an excitatory neurotransmitter involving postsynaptic stimulation of H1 and H2 receptors throughout the CNS, histamine plays a key role in attention and vigilance. In the brain, histamine regulates the sleep-wake cycle, sense of reward, emotion, learning, and neuroinflammation.
Cardiovascular System
Important physiological activities of histamine in the human organism include synaptic transmission, blood pressure control, allergic response, and cellular growth control. H1 receptor activation leads to vasodilation and increased vascular permeability, while H2 receptor activation on cardiac tissue contributes to positive chronotropic and inotropic effects. In large amounts β as occurs in systemic anaphylaxis or severe histamine poisoning β these effects can produce dangerous hypotension and cardiovascular compromise.
Histamine and Narcolepsy
Since brain histamine has a strong impact on the vigilant state, the involvement of the histaminergic system in narcolepsy has been extensively studied. Several reports showed lower histamine levels in the CSF of narcolepsy patients (Kanbayashi et al., 2009; Nishino et al., 2009) and a recent study indicated the involvement of impaired histaminergic neurotransmission in narcoleptic children (Franco et al., 2019).
6. Scientific Evidence by Area of Use
6.1 Histamine Intolerance (HIT): Clinical Evidence
Histamine intolerance (HIT) is defined as a disequilibrium between dietary histamine and the capacity of the organism to degrade intestinal histamine, leading to the appearance of intestinal and extra-intestinal symptoms. It is thought to be associated with low activity or blockade of diamine oxidase (DAO), the main enzyme for histamine degradation.
The diagnosis is hampered by the lack of a validated biomarker and is mainly based on clinical assessment and response to a low-histamine diet and reintroduction. Numerous clinical studies have provided data on the prevalence of low plasma DAO levels in individuals showing symptoms of histamine intolerance, mainly headaches and gastrointestinal or dermatological disorders. Although certain studies have limitations in design or number of participants, the majority point to an association between symptoms and DAO deficiency, establishing a general trend that supports the key role of DAO in the etiology of these disorders.
Study specifics β DAO supplementation: The enzyme diamine oxidase (DAO) is considered for the gastrointestinal degradation of histamine. An open-label interventional pilot study identified 28 patients with HIT, who were instructed to take DAO capsules before meals for four weeks, followed by a period without DAO supplementation. A 22-symptom questionnaire was used. All symptoms improved significantly during oral DAO supplementation. During the follow-up period without DAO supplementation, symptom scores increased again, and a significant reduction of every HIT-related symptom and its intensity due to DAO oral supplements was demonstrated. This was an open-label, uncontrolled pilot study (NCT03298568), and the evidence should be considered preliminary.
DAO as a biomarker: Symptom severity was associated with the degree of DAO deficiency. Patients with DAO values between 3 and 10 U/mL showed the best response to treatment (low-histamine diet and/or DAO supplementation). DAO value could arguably be considered as a predictor of clinical response to treatment. Prospective studies are needed to confirm these data.
HIT and fibromyalgia: A double-blind, placebo-controlled clinical trial on DAO supplementation in women with fibromyalgia was presented as one of the first studies to provide evidence of the therapeutic benefits of DAO in managing chronic pain and fatigue characteristic of fibromyalgia. The authors found that exogenous DAO supplementation significantly reduced pain in patients with HIT, underscoring the role of histamine in fibromyalgia symptoms.
Genetic factors: DAO deficiency can have a genetic background, as certain polymorphisms for genes encoding the DAO enzyme have been associated with HIT symptoms.
Overall evidence strength for HIT: The body of clinical evidence is growing but remains limited by small sample sizes, heterogeneous methodologies, and the lack of a universally validated diagnostic biomarker. The clinical efficacy of diamine oxidase supplementation for histamine intolerance remains inconclusive according to current NIH/StatPearls review, and larger, properly controlled randomized trials are needed.
6.2 Scombroid / Histamine Food Poisoning
According to the qualitative risk characterization performed by EFSA, exposure to histamine (95th-percentile value) in fermented foods does not go beyond the safe threshold of 50 mg/meal/person. Histamine intoxication is caused by the intake of foods with high levels of histamine; according to official European Union reports, more than 90% of outbreaks registered in recent years were caused by the consumption of fish and seafood products.
Based on the No Observed Adverse Effect Level (NOAEL) of 50 mg for histamine in both healthy volunteers and sensitive individuals, an Acute Reference Dose (ARfD) was established. The assessment indicated that healthy adults consuming less than 50 mg of histamine per meal were at a lower risk of experiencing adverse health effects. Histamine concentrations exceeding 200 mg/kg in fish and fishery products may pose significant health risks to consumers, according to a 2012 FAO/WHO report.
The symptoms of scombroid poisoning develop after a few hours of exposure and are similar to allergic reactions, such as flushing of the face, neck, and upper arms, oral numbness and/or burning, headache, and heart palpitations. The symptoms of histamine (scombrotoxin) poisoning include flushing, headache, nausea, itching, rash, and altered blood pressure, with EFSA (2011) noting fatalities in extreme cases.
Evidence strength: The link between elevated dietary histamine and scombroid poisoning is well-established and supported by epidemiological outbreak data, regulatory assessments, and dose-response analyses. This represents one of the strongest evidence bases in histamine science from a food-safety perspective.
6.3 Histamine in Sleep Pharmacology
Histamine was first identified in the brain about 50 years ago, but only in recent years have researchers gained an understanding of how it regulates sleep/wake behavior. Translational research has moved from basic science to new clinical trials demonstrating the usefulness of drugs that enhance histamine signaling.
The histaminergic system is receiving increased attention as much has been learned about the normal functions of this system and how its dysfunction may contribute to clinical sleep disorders. A symposium at the Sleep 2018 meeting focused on the normal functions of the histamine system, how daily variations in activity of histaminergic neurons help drive circadian rhythms of sleep and wake, and how new compounds that enhance histamine signaling improve wake and cataplexy in narcolepsy.
Evidence strength: Evidence for histamine's central role in sleep-wake regulation is robust at the preclinical level, and translational clinical evidence is growing, particularly in the context of sedating first-generation antihistamines and the therapeutic development of H3 antagonists for narcolepsy and other sleep disorders.
6.4 Histamine H4 Receptor in Inflammatory and Immune Disorders
The histamine H4 receptor was discovered through molecular biology advances. This receptor is mainly expressed in various cells involved in the immune system, and several H4 antagonists are now under clinical trials for asthma, psoriasis, and rheumatoid arthritis, although the functional involvement of H4 receptors in the CNS remains inconclusive. H4 receptor antagonists show promising anti-inflammatory activity against pruritus and atopic dermatitis but have yet to secure regulatory approval.
Evidence strength: H4 receptor pharmacology represents an active and promising area of clinical research. Trials are ongoing, but no H4-targeted therapeutic has achieved regulatory approval as of the available literature. Evidence is therefore early-phase.
7. Dosage Forms and Dosages Reported in Studies
There is no recommended dietary intake for histamine itself as a supplement. The following dosage information is drawn directly from cited sources and relates to study-specific contexts:
- Histamine intolerance research β NOAEL threshold: Based on EFSA's 2011 assessment, an NOAEL of 50 mg histamine per meal in both healthy volunteers and sensitive individuals was established as the basis for the Acute Reference Dose. Healthy adults consuming less than 50 mg of histamine per meal were at a lower risk of adverse health effects.
- Fish safety threshold (FAO/WHO, 2012): Histamine concentrations exceeding 200 mg/kg in fish and fishery products may pose significant health risks to consumers.
- FDA regulatory limit: The FDA limit is typically 50 ppm (parts per million) for many fish species.
- DAO supplementation (pilot clinical trial): An open-label pilot study of 28 HIT patients had participants take DAO capsules before meals for four weeks. Specific dose quantities (in U or mg) were not reported in the abstract data available.
- DAO biomarker cutoff: Serum DAO levels below 10 IU/mL were used to confirm histamine intolerance in clinical assessments.
8. Safety Considerations and Drug Interactions
Histamine Toxicity from Food
Several fermented foods may contain biogenic amines including histamine at levels above documented toxic doses. Dietary exposure to foods containing high levels of histamine is associated with many adverse health effects, such as migraines, elevated blood pressure, and tachycardia. Biogenic amine-mediated toxicity may occur at levels a hundred times below regulatory and suggested toxic doses, depending on an individual's sensitivity and factors such as alcohol consumption and certain medications.
Alcohol and Histamine
Histamine intolerance is a long-known, multifaceted clinical condition triggered by histamine-rich foods and alcohol and/or by drugs that liberate histamine or block DAO, the main enzyme involved in the metabolism of ingested histamine. Alcohol is understood to both contain histamine and to inhibit DAO activity, compounding histamine burden in susceptible individuals.
Medications That Inhibit DAO Activity
In in vitro testing against purified human diamine oxidase, chloroquine and clavulanic acid showed the greatest inhibition potential (greater than 90%). Cimetidine and verapamil showed inhibition of about 50%. Moderate influence on DAO was caused by isoniazid, metamizole, acetyl cysteine, and amitriptyline (greater than 20%).
Some medications inhibit histamine-degrading enzymes and can therefore increase histamine levels: MAO inhibitors (monoamine oxidase inhibitors), used for depression, can slow down the breakdown of histamine. Antibiotics can reduce the activity of DAO. Contraceptives containing estrogen can reduce DAO activity and thus influence histamine breakdown.
Medications That Inhibit HNMT
The histamine receptor H1 antagonist diphenhydramine, the antimalarial drug amodiaquine, the antifolate drug metoprine, and the anticholinesterase drug tacrine (an early drug for Alzheimer's disease) are all potent HNMT inhibitors, with inhibition constants in the range of 10β100 nM. Despite their structural diversity, they all occupy the histamine-binding site, thus blocking access to the enzyme's active site.
Special Populations
Patients with mastocytosis, systemic mast cell activation syndrome (MCAS), or chronic urticaria may have elevated histamine levels due to endogenous overproduction rather than insufficient degradation. In such cases, DAO supplementation may be insufficient or ineffective, and its use should be part of a broader treatment strategy.
As DAO is naturally produced in the kidney and partially cleared by the liver, individuals with compromised renal or hepatic function may metabolize DAO differently. The implications of this are not well understood.
HIT Misdiagnosis Risk
Diamine oxidase (DAO) deficiency, a key marker of histamine intolerance, often mimics anxiety or panic disorders, leading to misdiagnosis and delayed treatment. Clinical presentations include chronic palpitations, nasal congestion, and gastrointestinal disturbances. Serum DAO levels below 10 IU/mL confirmed HIT in reported cases, and treatment with a low-histamine diet and DAO supplementation significantly improved symptoms.
Alcohol and DAO Inhibition Summary
The ingestion of histamine-rich food or alcohol may provoke heterogeneous symptoms and signs such as diarrhea, headache, rhinoconjunctivitis, asthma, hypotension, arrhythmia, urticaria, pruritus, and flushing. Additionally, several drugs have been suggested to induce histamine release or block DAO.
References
Go back